Cutaneous mucinosis and skin necrosis complicates interferon alfacon-1 (consensus interferon) treatment of chronic hepatitis C

European Journal of Medical Research

Volumn 10, Issue 2, 2005, Pages 63-67

  Siewert, Elmar ^a   Weyers, W ^b   Dietrich, C G ^a   Geier, A ^a   Lammert, F ^a   Matern, S ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Einsendungslabor fur Dermatopathol   (Germany)

Author keywords

Consensus interferon; Cutaneous mucinosis; Hepatitis C virus; Skin necrosis; Skin ulceration

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; MUCIN; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CLINICAL PROTOCOL; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERESTHESIA; INJECTION SITE REACTION; LABORATORY TEST; LIVER BIOPSY; MALE; MUCINOSIS; MYALGIA; RANDOMIZATION; SCAR FORMATION; SELF INJECTION; SKIN BIOPSY; SKIN NECROSIS; SKIN ULCER; THORAX PAIN;

ANTIVIRAL AGENTS; BIOPSY; ERYTHEMA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MIDDLE AGED; MUCINOSES; NECROSIS; SKIN; TREATMENT OUTCOME;

EID: 14844321550     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S (1998) Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499
2. Fleig WE, Krummenerl P, Leßke J, Dienes HP, Zeuzem S, Schmiegel W-H, Häussinger D, Brudelski, M, Manns MP (2004) Diagnosis and treatment of acute and chronic hepatitis-C-virus infection: consensus statement. Z Gastroenterol 42: 703-733
3. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171.
4. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) (2004) Chronic hepatitis B: update of recommendations. Hepatology 39: 857-861.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-998
7. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG Jr, Witt K, Blatt LM (1998) Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 27: 1136-1143
8. Melian EB, Plosker GL (2001) Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61: 1661-1691
9. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355
10. Fried MW (2002) Side effects of therapy of hepatitis C and their Management. Hepatology 36: S237-S244
11. Shiffman ML (2004) Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 3: 5-10
12. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069.
13. Dalekos GN, Hatzis J, Tsianos EV (1998) Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis. Ann Intern Med 128: 409-410
14. Heinzerling L, Dummer R, Burg G, Schmid-Grendelmeier P (2002) Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient. Eur J Dermatol 12: 194-197
15. Kurzen H, Petzold D, Hartschuh W, Jappe U (2002) Cutaneous necrosis after subcutaneous injection of polyethylen-glycol-modified interferon alpha. Acta Derm Venereol 82: 310-312
16. Bessis D, Charron A, Rouzier-Panis R, Blatiere V, Guilhou JJ, Reynes (2002) Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient. Eur J Dermatol 12: 99-102
17. Elgart GW, Sheremata W, Ahn YS (1997) Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum. J Am Acad Dermatol 37: 553-558
18. Sickler JB, Simmons RA, Cobb DK, Sherman KE (1998) Cutaneous necrosis associated with interferon alpha-2b. Am J Gastroenterol 93: 463-464
19. Conlon KC, Urba WJ, Smith JW II, Steis RG, Longo DL, Clark JW (1990) Exacerbation of symptoms of autoimmune diesease in patients receiving alpha-interferon therapy. Cancer 65: 2237-2242
20. Jackson EM, JC English III (2002) Diffuse cutaneous mucinoses. Dermatol Clin 20: 493-501
21. Rongioletti F Rebora A (2001) Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 23: 257-267
22. Rongioletti F, Rebora A (2001) Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 44: 273-281
23. Biro DE, Lynfield YC, Heilman ER (1995) Papular mucionosis and human immunodefieciency virus infection. Cutis 55: 113-114
24. Benito-León J, Borbujo J, Cortés L (2002) Cutaneous mucinoses complicating interferon beta-1b therapy. Eur Neurol 47: 123-124
25. Kumar N, Rodriguez M (2004) Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 10: 85-86
26. Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, Kawada N, Shirasaki F, Takehara K, Sugiyama K, Fujii M, Yamauchi H, Nakao A, de Crombrugghe B, Watanabe T, Okazaki I (2003) Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38: 890-899